Scientific publications with SCQM data

Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index: a cohort study in a Swiss registry

Comparative Treatment Effectiveness In Rheumatoid Arthritis With And Without Concomitant Sjögren’s Disease - Results From The Swiss Clinical Quality Management Cohort

Anti-Apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox in rheumatoid arthritis

Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: results from the EuroSpA Research Collaboration Network.

Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice

Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network

Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment

Enthesitis in a European registry-based cohort of patients with psoriaticarthritis treated with tumour necrosis factor inhibitors: clinical burden,patient-reported outcomes, and treatment response

Explainable deep learning for disease activity prediction in chronic inflammatory joint diseases

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries

Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?

Detection and Grading of Radiographic Hand Osteoarthritis Using an Automated Machine Learning Platform

Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA

Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries: a survey 

Impact of Blue-Collar vs. White-Collar Occupations on disease burden in Psoriatic Arthritis Patients: A Swiss Clinical Quality Management in Rheumatic Diseases Cohort Study

Impact of patient characteristics on ASDAS disease activity state cut-offs in axial spondyloarthritis: results from nine European rheumatology registries 

Radiographic Progression in Patients with Rheumatoid Arthritis in Clinical Remission or Low Disease Activity: Results from a Swiss National Registry (SCQM)

Characterisation of patients with axial psoriatic arthritis and patients with axial spondyloarthritis and concomitant psoriasis in the SCQM registry

Site-specific assessment of spinal radiographic progression improves detection of TNF blocker-associated disease modification in axial spondyloarthritis: Longitudinal observational data from the Swiss Clinical Quality Management Registry

Anaemia is associated with higher disease activity in axial spondyloarthritis, but is not an independent predictor of spinal radiographic progression: Data from the Swiss Clinical Quality Management Registry

One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment

Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries

Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs

Impact of sex on spinal radiographic progression in axial spondyloarthritis: a longitudinal Swiss cohort analysis over a period of 10 years

Obesity represents an increasing health issue in axial spondyloarthritis, particularly affecting socially disadvantaged patients

Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care

Longitudinal associations between body mass index and changes indisease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab

Impact of SARS-CoV2 infection on anti-Apolipoprotein A-1 IgG response in inflammatory rheumatic diseases.

Characterization of serum biomarkers and antibody responses against Prevotella spp. in preclinical and new-onset phase of rheumatic diseases

Biological disease-modifying anti-rheumatic drugs are equally effective in psoriatic arthritis patients with low and high joint counts

Differences and similarities between the latest EULAR/ASAS-EULAR recommendations and national guidelines for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries

“Early” axial spondyloarthritis according to the 2023 ASAS consensus definition: characterization of patients and retention of a first TNF inhibitor in a large observational registry

Evaluation and comparison of oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: results from the international TOCERRA and PANABA observational collaborative studies

Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)

A potential role for chlamydial infection in rheumatoid arthritis development

Second and third TNF inhibitors in European patients with axial spondyloarthritis: Effectiveness and impact of reason for withdrawal from the previous treatment

Commonalities and differences in set-up and data collection across European spondyloarthritis registries

Detection and Grading of Radiographic Hand Osteoarthritis Using an Automated Machine Learning Platform

Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry 

Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index: a cohort study in the Swiss Clinical Quality Management cohort

Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort

Sacroiliac joint radiographic progression in axial spondyloarthritis is retarded by the therapeutic use of TNF inhibitors: 12- year data from the SCQM registry

Does tenosynovitis of the hand detected by B-mode ultrasound predict loss of clinical remission in rheumatoid arthritis? Results from a real-life cohort.

The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis

Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy

Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss Clinical Quality Management cohort

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland

Collaborative challenges of multi-cohort project in pharmacogenetics - why time is essential for meaningful collaborations

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases

Pregnancy and neonatal outcomes in women with axial spondyloarthritis: pooled data analysis from the European Network of Pregnancy Registries in Rheumatology (EuNeP)

Lower odds of remission among women with rheumatoid arthritis: A cohort study in the Swiss Clinical Quality Management cohort

Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling

Combining individual patient data from randomized and non-randomized studies to predict real-world effectiveness of interventions

Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high with worsening of patient-related outcomes

Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors

Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis

Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA for the severity of rheumatoid arthritis

Impact of assessing patient-reported outcomes with mobile apps on patient-provider interaction

European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response

Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration

Site-specific resolution of enthesitis in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors

Personalized prediction of disease activity in patients with rheumatoid arthritis using an adaptive deep neural network

Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries

Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland

Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab

Prediction of sustained biologic and targeted synthetic DMARD free remission in rheumatoid arthritis patients

The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries

Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.

Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort

Personalized Prediction of Disease Activity in Patients with Rheumatoid Arthritis Using an Adaptive Deep Neural Network

Serum calprotectin: A promising biomarker in rheumatoid arthritis and axial spondyloarthritis

Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the disease

Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis

Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort

Differences between men and women with nonradiographic axial spondyloarthritis: Clinical characteristics and treatment effectiveness in a real-life prospective cohort

Tumour Necrosis Factor Inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: combined analysis of European biologics databases

Discordances between clinical and ultrasound measurements of disease activity among RA patients followed in real life

A Dynamic Deep Neural Network For Multimodal Clinical Data Analysis

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration

Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases : results from the Swiss Clinical Quality Management cohort

Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts

Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpA

Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: Results from the SCQM cohort

Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution

European Network of Pregnancy Registers in Rheumatology (EuNeP)- A n overview of procedures and data collection

Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years

Treatment response and drug retention rates in 24 195 biologic-naive patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration

Towards standardized patient reported physical function outcome reporting: linking ten commonly used questionnaires to a common metric

Bone erosion scoring for rheumatoid arthritis with deep convolutional neural networks

The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritis

Brief report: Influence of Disease Activity in Rheumatoid Arthritis on Radiographic Progression of Concomitant Interphalangeal Joint Osteoarthritis

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab inpatients with axial spondyloarthritis

Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis

Response to tumor necrosis factor inhibition in male and female patients with ankylosing spondylitis: Data from a Swiss Cohort

Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort

Incidence and Prevalence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis

Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries

Comparison of serological biomarkers in rheumatoid arthritis and their combination to improve diagnostic performance

TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: Results from the Swiss Clinical Quality Management cohort

Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: Results from the swiss prospective observational cohort

Can ultrasound be used to predict loss of remission in patients with RA in a real-life setting? A multicenter cohort study

Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life

Rituximab retreatment in rheumatoid arthritis in a real-life cohort: Data from the CERERRA collaboration

Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the “pan-European registry collaboration for abatacept (PANABA)

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics : results from a collaborative project of 11 European biologic registers

Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis

Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)

Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration

Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis Results from the Swiss Clinical Quality Management Cohort

Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis

Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study

Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: Results from a European collaborative study

Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity with Better Effectiveness of Abatacept: Results from the Pan-European Registry Analysis

The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis

Treatment with tumor necrosis factor inhibitors in axial spondyloarthritis: Comparison between private rheumatology practices and academic centers in a large observational cohort

Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: Data from the Swiss Clinical Quality Management Registry

Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study

The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis

Rituximab done: What's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries

Joint damage progression in patients with rheumatoid arthritis in clinical remission. Do biologics perform better than synthetic antirheumatic drugs?

Age at symptom onset in ankylosing spondylitis: Is there a gender difference?

Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: A prospective cohort study

Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis

Ultrasound evaluation of synovitis in RA: Correlation with clinical disease activity and sensitivity to change in an observational cohort study

Persistence of ultrasound synovitis in patients with rheumatoid arthritis fulfilling the DAS28 and/or the new ACR/EULAR RA remission definitions: Results of an observational cohort study

Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: Results from a large observational cohort

Smoking and spondyloarthritis

Recommendations for the use of ultrasound in rheumatoid arthritis: Literature review and SONAR score experience

Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: Results from the Swiss SCQM registry

Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: Results of a 1-year follow-up study from the CERERRA collaboration

Pain as an important predictor of psychosocial health in patients with rheumatoid arthritis

Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients

Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: Pooled data from 10 European registries

The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study.

Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion

A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients

The effect of alcohol on radiographic progression in rheumatoid arthritis

The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: A population-based study

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis

Cigarette smoking and radiographic progression in rheumatoid arthritis

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents

Tolerance and effectiveness of anti-tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: A population-based cohort study

Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis

The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: A population-based study

Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the community

Clinical quality management in rheumatoid arthritis: Putting theory into practice